Deal paves way for global rollout

Posted 4 August 2026 PM

Pharmanovia has inked a deal worth up to $601.9 million with Chinese biotech IMPACT Therapeutics to commercialise senaparib in 66 countries, including Australia.

The highly potent PARP1/2 inhibitor developed by the Shanghai headquartered biotech is currently on approved in China, where it also reimbursed via the National Reimbursed Drug List as a first-line maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy.

To see the whole article please log in.

Tiffany Walker

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here